Success! Your message has been sent to us.
Error! There was an error sending your message.

Center for Clinical Neuroscience

State of the art and research, technologically advanced assessment and treatment.

  • Research validated diagnostic interview protocol (SCID)
  • Pharmacogenomic testing; Genetically informed psychopharmacology
  • Deep Transcranial Magnetic Stimulation (dTMS)
  • Neurofeedback for impulse regulation, anxiety, information processing
  • ReCognition: Brain gym for cognitive enhancement
  • Psychiatric Medication
  • Neuro-imaging: Quantitative EEG (Qeeg)
  • Neuro-cognitive assessment: Attention, working memory, executive function
  • Respiratory Sinus Arrhythmia (RSA) Real-time autonomic dysregulation
  • Collaborative consultation with emerging adult, family and professionals
  • User-friendly assessment report & recommendations

Increasingly, the use of neuroscience technology has allowed for improved understanding of complex conditions and insufficient response to treatment.

The Qeeg provides a 3D mapping of the electrical activity and networking relationships within the brain.

Pharmacogenetics is the study of how an individual’s DNA affects their response to medication. Genomic mapping informs issues of dosing, efficacy, medication intolerance and drug interactions. Findings are matched with databases that guide specific prescriptive choices.

ReCognition is Yellowbrick’s cognitive enhancement “Brain Gym” offering online training programs strengthening cognitive processes such as attention, concentration, working memory and problem solving which are crucial to effective role performance.

Neuro-cognitive testing examines discrete cognitive and mental processing functions.

Expert clinical judgment in applying these neuroscience techniques may reveal previously undetected diagnosis or impairments, as well as “signature treatment response patterns” which inform therapeutic strategy.

Yellowbrick employs multiple neuro-modulation techniques including Deep Transcranial Magnetic Stimulation (dTMS) as an FDA approved treatment for depression which has not responded to medication. Neurofeedback allows for redirecting de-regulated neural networks to reduce anxiety, cognitive impairment and impulsivity. Direct current stimulation relieves anxiety and improves sleep by inducing an alpha brain state. Each of these interventions is often highly effective quickly, non-invasive and without adverse effects.

  • Center for Clinical Neuroscience
  • Emerging Adult Assessment Center
  • The Residence
  • Life Strategies Program IOP
  • Trauma Recovery Program (Evening IOP)
  • Eating Disorder Service
  • Career Development Center
  • Core Competence Home Health Services
  • Campus Competence

Deep TMS - Transcranial Magnetic Stimulation

Brainsway Deep Transcranial Magnetic Stimulation (Deep TMS) System for Treatment of Major Depressive Disorder

If you are considering Brainsway Deep TMS treatment for treatment of Depression you should review this information and discuss the information with your doctor in order to understand more about:

You have been diagnosed with Major Depressive Disorder and your doctor has recommended treatment with the Brainsway Deep TMS Treatment to treat symptoms of your depression. Brainsway Deep TMS Treatment has been shown to be safe and effective in the treatment of patients with Major Depressive Disorder. Your Health Care Provider (psychiatrist or physician) will review your medical and depression history to help determine if Brainsway Deep TMS Treatment is appropriate for you or not. The treatment is performed under your psychiatrist’s supervision. Neither anesthesia nor sedation is required. You will be awake and alert during the treatment sessions. The treatment sessions include daily treatments for a period of 4 weeks. Each treatment session lasts approximately 20-30 minutes. Your doctor may consider further biweekly maintenance treatments in order to continue treating your depression.

DTMS stands for “Deep Transcranial Magnetic Stimulation”. DTMS is a non-invasive procedure, involving stimulation of a part of the brain called the Left Prefrontal Cortex. The stimulation activates the nerve cells in this region of the brain and improves depressive symptoms. The stimulation is produced by a treatment “coil” contained in a helmet. During treatment, the helmet is gently positioned on the left front side of your head, over this region of the brain. Short pulses of electricity sent through the treatment coil generate magnetic fields that turn on and off very rapidly. These magnetic fields are similar to those used in magnetic resonance imaging (MRI) systems. The magnetic field goes through the head and induces a weak electrical current that briefly activates the nerve cells in this region of the brain and improves depressive symptoms.

Indications for Use The Brainsway Deep TMS System is indicated for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode.

Safety of the Brainsway Deep TMS System was demonstrated in a clinical study involving 233 patients with moderate to severe Major Depressive Disorder. The patients ranged in age from 22 to 68 years. This section summarizes the adverse events and side effects reported in the clinical study with the Brainsway Deep TMS System.

  • There were no deaths in patients who took part in the clinical trial.
  • Systemic side effects such as weight gain, dry mouth and sexual problems were not observed.
  • Tests of memory function during treatment showed no change during the clinical trial.

You should discuss the warnings and precautions related to the DTMS Treatment with your doctor to determine if any precautions should be taken prior to or during your treatment with Brainsway Deep TMS System.

There was one case of a seizure (also called convulsions) reported in the clinical study with the Brainsway DTMS System. This seizure was due to high alcohol consumption the night before treatment. 3 more seizures (out of approximately 50,000 treatment sessions) were reported in other studies with the Brainsway DTMS System in subjects on high doses of antidepressants, which are known to increase the risk of a seizure. None of the subjects who have experienced DTMS-induced seizure have suffered lasting physical sequelae. You should discuss with your doctor if you have had a seizure, or if you have a medical condition or change in a medical condition which may put you at increased risk of having a seizure, e.g., brain injury, change in medications, change in electrolyte balance, etc. Your doctor will decide if it is appropriate for you to receive Brainsway DTMS Treatment.

Your antidepressant medications may be tapered down prior to the Brainsway DTMS Treatment. You may feel uncomfortable or be unable to tolerate the tapering of medications. Your depression may become worse before you begin to see an improvement in your symptoms. Increased mood lability and suicidality may also result from tapering medications. Brainsway DTMS Treatment may require several weeks of treatment before symptom improvement occurs. Your doctor will monitor you for worsening depressive symptoms or signs or symptoms of suicidal behavior during the course of the treatment. You should also inform your doctor if you have any behavioral changes, such as worsening of depression, suicide attempts and ideations, increased aggressiveness, euphoria or irritability. Your family and caregiver should also be aware that if such behavioral changes appear, they should inform the treatment administrator immediately. Your doctor will determine whether Brainsway DTMS treatment should be discontinued and, if so, what other treatment options are available

The long term safety of the Brainsway DTMS Treatment has been demonstrated in a clinical study. During the full course of 16 weeks of ongoing treatment, the treatment was safely tolerated. Furthermore, no negative effects of treatment were seen during a 3 month follow-up period. Longer term effects of exposure to the DTMS treatment are not known. However, exposure to other devices (such as MRI scanners) with the same type and strength of magnetic fields produced by the Brainsway DTMS coil are not associated with significant short-term or long-term safety concerns.

Application site pain or discomfort was reported in 25% and 29% of patients who received the Brainsway DTMS Treatment, and in less than 1% and 4.1% of the patients who received the sham (placebo) treatment. Pain in jaw was reported in 10.2% of patients who received the Brainsway DTMS Treatment, and in less than 1% of the patients who received the sham treatment. This indicates that these side effects are caused by the Brainsway DTMS Treatment.

You should Inform the treatment administrator if you feel pain or discomfort during the treatment. The DTMS helmet may be slightly adjusted on your head to relieve the pain or discomfort. Pain and discomfort associated with treatment usually gets better or goes away altogether with successive treatments. Headaches were reported in 47% of patients who received the Brainsway DTMS Treatment, and in 36% of the patients who received the sham (placebo) treatment. This indicates that headaches were not necessarily caused by the Brainsway DTMS Treatment.

Headaches usually get better or go away altogether with successive treatments. Headaches may also be relieved by using common over-the-counter pain medications such as acetaminophen. Other side effects which may occur but are not necessarily caused by the Brainsway DTMS Treatment include muscle twitching, back pain, anxiety or insomnia.

The safety and effectiveness of the Brainsway Deep TMS System for treatment of Major Depressive Disorder was demonstrated in a prospective, double blind, randomized, controlled, multi-center trial. The study was conducted at 20 study sites in the United States (13 sites), Israel (4 sites), Germany (2 sites) and Canada (1 site). During the initial treatment phase, TMS sessions were performed daily for 4 weeks and during the maintenance phase, subjects were treated twice a week for another 12 weeks.

The primary endpoint was the change from baseline (i.e., the starting score before treatment) in a standard scale for measuring depression symptoms, known as the Hamilton Depression Rating Scale (HDRS). The model estimated mean change from baseline in HDRS scores in the Deep TMS group across 5 weeks compared to the sham group was statistically significant. The response rate (meaning the percent of patients who had a reduction in HDRS scores of at least 50%) was significantly better in the Deep TMS group compared to the sham group. The remission rate (meaning the percent of patients who had a reduction in HDRS score to less than 10 points) was significantly better in the Deep TMS group compared to the sham group. There was a statistically significant improvement in quality of life in patients treated with the Deep TMS treatment, according to the difference in Q-LES-Q scores between the DTMS and sham groups. These results do not include 13% of subjects who did not receive the adequate DTMS treatment regimen and therefore, the effectiveness of the DTMS treatment was not as good in these subjects. Of these subjects receiving reduced intensity of DTMS treatment, some had a high Motor Threshold and therefore could not receive the adequate DTMS treatment regimen. Your Motor Threshold will be measured prior to the first treatment session and if it is too high, your doctor will discuss with you the appropriateness of receiving the DTMS treatment. Another few of these subjects did not receive the adequate DTMS treatment regimen, due to discomfort or pain during the treatment.

The efficacy of the Deep TMS Treatment was still seen at 16 weeks, based on a statistically significant change from baseline in HDRS scores (p=0.0259) and a significantly better response rate in the Deep TMS group compared to the sham group (p=0.0086). The efficacy of the DTMS Treatment, based on statistically significant differences in the CGI-S, CGI-I, PGI and GAF scores, was demonstrated at 5 weeks and also maintained at 16 weeks. No significant differences were found in the SF-36 scores, however all the SF-36 Quality of Life parameters were better in the Deep TMS group than in the sham group.

You may ask your doctor for more information regarding the clinical study.

The Brainsway Deep TMS System has been shown to be safe and effective for the treatment of Major Depressive Disorder (MDD). You should discuss the treatment with your doctor to ensure that the Brainsway Deep TMS Treatment is the right treatment for you.

Most patients who benefit from Brainsway Deep TMS experience results by the third or fourth week of treatment. Some patients may experience results in less time. The Brainsway Deep TMS Treatment should be administered daily for four weeks, following by 12 weeks of biweekly treatment. This is the treatment schedule that has been demonstrated as safe and effective in the clinical study.

As with any antidepressant treatment, there is a risk that your depression symptoms might worsen during the Brainsway Deep TMS Treatment. Your depression symptoms might also worsen, if you stopped taking antidepressant medications before starting the treatment. Inform your doctor immediately if your depression symptoms worsen.

The Brainsway Deep TMS Treatment has not been evaluated to be safe and effective for patients with suicidal ideation or who have recently attempted suicide.

Yellowbrick, located in Evanston, Illinois near Chicago offers Deep TMS treatment for Depression.

If you or someone you know is interested in Brainsway Deep TMS treatment for treatment of Depression, please use our confidential contact form to send us a message. Our Assessment Center will respond to you as promptly as possible.


ReCognition is an online compendium of cognitive exercises, presented as video games, guided by qualified professionals for the purpose of conducting comprehensive and effective cognitive rehabilitation therapy or cognitive skills training. ReCognition contains therapy exercises divided into six Tracks consisting of Attention Skills, Executive Skills, Memory Skills, Visuospatial Skills and Communication Skills. Each Track contains up to 15 individual exercises with up to four Levels of complexity. There are 84 exercises in total. Advance is automatic based upon patient performance and completion at the current level.

The ability to pay attention, persist in concentration, retain information in working memory, accurately process and think towards problem solving and strategic planning all affect an individual’s sense of well-being and functioning.

It is quite common for psychiatric conditions to affect cognitive functioning. This is evident in an extreme form when depression in the elderly presents as (pseudo)dementia and is common in depression across the ages. The heterogenous spectrum of psychotic illnesses are now understood to have cognitive impairment as a nuclear feature which is often present years before onset of explicitly psychotic symptoms and can be detected in varying degrees among asymptomatic relatives. Anxiety disorders, PTSD and OCD all involve cognitive lapses in attention and concentration. ADHD and learning disabilities are neurodevelopmental conditions affecting cognitive processing and executive functioning. Traumatic brain injury (TBI) may have cognitive sequelae. Recent research is detecting cognitive fog as a not uncommon finding post-Covid infection. The ongoing process of aging involves a normative evolving loss of the highest levels of cognitive performance.

Cognitive rehabilitation or cognitive skills training is a therapeutic intervention designed to improve an individual's ability to more effectively and efficiently utilize their attention, executive, memory, visuospatial, problem solving and communication skills. The rehabilitation or training consists of planned exercises that place demands on one's cognitive/intellectual skills in such a way that the person would have to improve upon their existing skill set or acquire new skill sets in order to successfully complete the tasks.

Psychiatric Medication

The Yellowbrick Center for Clinical Neuroscience (CCN) in Evanston, just north of Chicago, Illinois, is committed to providing the patients with cutting-edge, scientifically proven techniques for the diagnosis and treatment of emerging adults with complex mental health needs.

The mission of the CCN is to provide a range of scientifically-proven techniques to help those patients that have not responded, or not responded fully, to the typical approach to mental health problems.

Diagnosis is established through the use of the Structured Clinical Interview for Diagnosis, or SCID, which has been demonstrated to be the most reliable and valid method of determining psychiatric diagnosis. A convergence of other data then support the SCID in determining diagnosis, including a variety of psychometric instruments, as well as functional neuroimaging through the use of quantitative electroencephalography (qEEG).

Treatment recommendations often include medications, though a variety of non-medication based therapeutic modalities are also employed to provide the patient the highest level of support in the work of recovery from psychiatric struggle. Medication recommendation are guided by pharmacogenomic testing, a technique that allows recommendations to be based on individualized understanding of the patients metabolism and neurophysiology. Non-medication based modalities ranging from neuromodulatory techniques such as TMS and Alpha Stim to nutriceuticals (e. g. specific vitamins and minerals, Omega 3 supplementation, etc) to exercise, sleep hygiene and yoga.

Why is our treatment and philosophy unique?

In accordance with the Yellowbrick Model, the CCN approaches the mental health problems from a developmental, neurobiological perspective. Traditional psychiatric techniques are supplemented by understanding how a person’s struggles are manifesting in their brain, as well as their behavior. Therapeutic recommendations are based on a holistic understanding of the patient, informed by understanding their psychology and developmental history and, as importantly, their genetics and brain function.

Yellowbrick’s CCN places a priority emphasis on a consultative, collaborative partnership with patients and their families. Professionals provide consultative expertise assisting emerging adults in making fully informed choices regarding health and well-being.

What are concerns and positive results of psychiatric medication at Yellowbrick?

The use of pharmacogenomic testing – beginning to fulfill the promise of truly individualized medicine – allows us to understand what genetic vulnerabilities a patient may have to experiencing side effects from a given medication, or not being likely to experience intended therapeutic effects. While this technology is not yet at the point where we can tell which is the right medication, we can tell which medications are likely to be a bad choice, having a higher chance of side effects or lack of therapeutic effect. This can save patients unknown weeks and months of going the trial and error process of medication selection that characterized psychiatric practice prior to the advent of pharmacogenomics.

What are the most common needs and therapies for psychiatric medication?

Often, patients have tried one or more medications and failed to respond, respond fully, or have responded with side effects. For those patients who are not involved in the Yellowbrick Life Strategies IOP, the CCN can assist their treatment team in through a collaborative consultation. If a patient lacks a treatment team, we can assist them in finding expert care in their community.

The CCN is also able to offer non-medication modalities, such as TMS, in partnership with a patient’s current psychiatrist.

What to Expect from Treatment at the Yellowbrick CCN

A CCN consultation will involve the collection of previous medical records, conversation with current or past mental health providers, the collection of a DNA sample (done by a simple swab of the cheek), a variety of pen-and-paper and computer-based tests, several EEG-based tests, as well as an extensive psychiatric interview.

The typical CCN consult lasts 2 – 3 days, depending on the extent of the consult, number of records to review, etc. Consultations culminate in a collaboration conference in which the key findings and recommendations are discussed, so that any therapeutic recommendations can be implemented as quickly as possible. A full report of the consultation is prepared within 2-4 weeks following the consultation.

Our Specially Trained Mental Health Professionals

David H. Baron, MD, is the Senior Staff (Board Certified) Psychiatrist providing leadership, clinical and administrative oversight for the Center for Clinical Neuroscience.

Jesse Viner, MD, a Board Certified psychiatrist and psychoanalyst with four decades of experience, is the Founder and Executive Medical Director of Yellowbrick, overseeing all of the operations with Yellowbrick, including the CCN.



If you or someone you know is suffering from mental illness, please use our confidential contact form to send us a message. Our Assessment Center will respond to you as promptly as possible.

At Yellowbrick, emerging adults find their way home.

For more information, please contact Yellowbrick at 847-869-1500.

Success! Your message has been sent to us.
Error! There was an error sending your message.